Celgene has supported a funding round for Oncorus, an immuno-oncology treatment developer that is focusing on brain cancer.
US-based immuno-oncology therapy developer Oncorus closed a $57m series A round yesterday that featured pharmaceutical company Celgene.
The round was led by MPM Capital, through equal commitments from its MPM BV2014 fund and its Oncology Impact Fund, which is backed by financial services firm UBS. It also included Deerfield Management, Arkin Bio Ventures, Excelyrate Capital, Long March Investment Fund and MPM’s SunStates Fund.
Founded in 2015, Oncorus is working on an immunotherapy platform that uses viruses to destroy cancer cells…
